ABBV-744 as a potential therapeutic option for aggressive cancers Secrets
These side effects have been notably milder when compared with an inhibitor of both bromodomains. A detailed molecular Investigation also exposed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen Taylorthen boost H3K27Ac at this region. Chromatin hyperacetylation could raise the accessibil